Novavax is trading 6.8% down at $9.18 after opening-market selling on September 10, 2026.
- The Nasdaq Composite is down 0.80% as investors reassess interest-rate expectations after elevated August producer-price inflation.
- No new company-specific negative announcement was identified.
- Novavax is scheduled to participate in a Citi BioPharma conference on September 10; its latest press-release listing contains no fresh adverse catalyst.